International Expansion of Japanese Medical Devices
First written in FY2016. 11 of 14 entries say "Advanced", first in FY2017. Latest entry: 2026-09-29.
6 other companies' latest entry also says "Advanced".
- 2026-09-29Advancedyoutu.beIt has been reported that the acquisition of a company with FDA-approved products and patents has moved overseas expansion from the planning and preparation stage to the execution of specific investments.
- FY2026AdvancedAnnual report
「Expansion into the Middle East and Asia, which is being pursued as the first phase of our strategy, is progressing smoothly through partnerships with local distributors. We are also accelerating preparations to obtain marketing approval in the United States, or FDA approval, as our next pillar of growth, and are promoting the establishment of a global quality management system (QMS) capable of accommodating FDA audits.」
Overseas expansion progressed to multiple execution stages: partnerships with distributors in the Middle East and Asia, preparations for US FDA approval, and establishment of a global QMS. - FY2025AdvancedAnnual report
「During the period of the medium-term management plan, we will rapidly expand sales channels to more than 10 countries, primarily in the Middle East and Asia, where products can be marketed based on Japanese domestic approval, while promptly addressing quality management system regulations and other requirements necessary to obtain US FDA and European CE approval.」
Overseas expansion became more concrete, progressing from the planning stage to developing sales channels in more than 10 countries during the medium-term plan period, addressing quality management requirements for FDA and CE approval, and expanding into OEM operations. - FY2021AdvancedAnnual report
「June 2020: Opened the JLL Malaysia Sdn. Bhd. Malaysian plant」
The overseas proprietary plant progressed from the construction and completion stages to the plant opening stage in June 2020, bringing the overseas production structure into operation. - FY2020AdvancedAnnual report
「During the consolidated fiscal year, as a first step into the North American market, we began exporting semi-finished EP catheters, albeit only certain limited models. We also established JLL Korea Co.,Ltd. as a new sales base in South Korea and are working to build our overseas sales structure.」
The company began exporting semi-finished EP catheters to North America and established JLL Korea Co.,Ltd. as a sales base in South Korea. Overseas sales progressed from the preparation stage to the establishment of a concrete sales structure. - FY2019RestatedAnnual report
「In our manufacturing function, we are proceeding with construction of our plant in Malaysia, our first overseas plant to be developed from the startup stage by the company itself. In addition to securing the supply capacity for our proprietary products, which continue to achieve strong growth,」
The company is continuing construction of its Malaysian plant and aims to secure overseas supply capacity for its proprietary products. No new milestone, such as completion, is stated beyond the start of construction reported in the previous filing. - FY2018AdvancedAnnual report
「In April this year, an overseas case involving an open stent graft, the first medical device intended for implantation in the body, was performed in Taiwan. We will continue building our overseas track record in preparation for the launch of sales in Europe, for which preparations are being made in parallel. On the manufacturing side, we have also begun construction of a plant in Malaysia and are proceeding with preparations with a view to full-scale overseas expansion of our proprietary products.」
The company performed an overseas case involving an open stent graft in Taiwan and began preparing for sales in Europe and constructing a plant in Malaysia. - FY2017AdvancedAnnual report
「For our proprietary products, active overseas expansion and expansion of our business domains are also future challenges. Although the domestic cardiovascular market is expected to continue growing, we believe that, in view of the company's medium- to long-term growth, we need to begin working now on expanding our proprietary products overseas.」
Overseas expansion of proprietary products originating in Japan was explicitly identified as a medium- to long-term growth challenge, rather than merely described as a possibility. - FY2016First statedAnnual report
「The company believes that it will be possible to expand overseas in the future as a medical device originating in Japan.」
The company describes the potential for overseas expansion of products that meet Japan's stringent functional and safety requirements in clinical settings.